Please assess the completion status of the following clinical trial:

Trial Title: Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or more~* A diagnosis of ocular hypertension or open-angle glaucoma and prior use of timolol or prostaglandin.~* Meet specific IOP level at visit 1 (screening), visit 2 (run-in) and visit 3 (baseline).~* Meet specific visual acuity score~* Are willing to follow instructions~* Have provided a written informed consent~Exclusion Criteria:~* Females who are pregnant, nursing or planning pregnancy~* IOP of 35 mmHg or greater~* Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or pigmentary glaucoma in either eye~* Suspected contraindication or hypersensitivity to study medications tafluprost or timolol (e.g. asthma, low pulse)or to wash-out medication brinzolamide~* Glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to Screening~* Use of contact lenses at Screening or during the study~* Presence of any abnormality or significant illness that could be expected to interfere with the patient safety or study parameters~* Current participation in another clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preservative-free timolol (Type: ACTIVE_COMPARATOR): None
- Preservative-free FDC and placebo (Type: EXPERIMENTAL): None
- Preservative-free tafluprost (Type: ACTIVE_COMPARATOR): None
- Preservative-free FDC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).